Columbia Care and The Center for Discovery announce collaborative study on the use of cannabis-derived medicines in treating epilepsy
Columbia Care and The Center for Discovery will join forces to study the use of Columbia Care’s ClaraCeed and ClaraCeed Ultra cannabis-derived tablets to reduce seizures.
Research will be led by neurologist Orrin Devinsky, M.D., director of the New York University Langone’s Comprehensive Epilepsy Center, and Dr. Terry Hamlin, associate executive director of The Center for Discovery.
Dr. Hamlin served as the principal investigator for the Epidiolex trials that ultimately led to Food and Drug Administration’s approval of the first cannabis-derived drug for the treatment of two rare forms of epilepsy.
“This partnership highlights Columbia Care’s dedication to evidence-based research validating the therapeutic benefits of our precisely manufactured cannabis-derived medicines,” Rosemary Mazanet, M.D., Ph.D., chief scientific officer and chair of the scientific advisory board at Columbia Care, said during the announcement. “We are honored to have been selected as a partner by the prestigious Center for Discovery as well as to have the opportunity to collaborate with such a world-renowned epilepsy expert as Dr. Devinsky. We are looking forward to better understanding how our ClaraCeed and ClaraCeed Ultra medications can best be utilized to treat patients who are suffering from treatment-resistant epilepsy safely and effectively.”
The study will enroll fifty Center for Discovery patients with drug-resistant epilepsy, aged 8-40 years old, who choose Columbia Care as their medical cannabis provider in accordance with current New York State Department of Health guidelines.